Diabetic Retinopathy Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Kodiak Sciences, Novartis, Regenxbio, OcuTerra, Bayer

 Breaking News
  • No posts were found

Diabetic Retinopathy Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Kodiak Sciences, Novartis, Regenxbio, OcuTerra, Bayer

November 07
21:40 2023
Diabetic Retinopathy Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Kodiak Sciences, Novartis, Regenxbio, OcuTerra, Bayer
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 50+ key pharma and biotech companies are working on 55+ pipeline drugs in the Diabetic Retinopathy therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Diabetic Retinopathy Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Diabetic Retinopathy Market. 

The Diabetic Retinopathy Pipeline report embraces in-depth commercial, regulatory, and Diabetic Retinopathy clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Diabetic Retinopathy drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Diabetic Retinopathy Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Diabetic Retinopathy treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Diabetic Retinopathy therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Diabetic Retinopathy companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Diabetic Retinopathy drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Diabetic Retinopathy therapeutic market.

Diabetic Retinopathy Therapeutics Landscape

There are approx. 50+ key companies developing therapies for Diabetic Retinopathy. Currently, Kodiak Sciences is leading the therapeutics market with its Diabetic Retinopathy drug candidates in the most advanced stage of clinical development.

Diabetic Retinopathy Companies Actively Working in the Therapeutic Market Include:

  • Kodiak Sciences

  • Novartis

  • Regenxbio Inc.

  • OcuTerra Therapeutics

  • Ocular Therapeutix

  • Bayer

  • RemeGen

  • Roche

  • Ocuphire Pharma

  • Adverum Biotechnologies

  • Boehringer Ingelheim

And Many Others

Emerging and Marketed Diabetic Retinopathy Drugs Covered in the Report Include:

  • KSI-301: Kodiak Sciences

  • Brolucizumab: Novartis

  • RGX 314: Regenxbio Inc.

  • OTT-166: OcuTerra Therapeutics

  • OTX-TKI: Ocular Therapeutix

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Diabetic Retinopathy Companies Working in the Market @


Analysis of Emerging Diabetic Retinopathy Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued and inactive candidates

Route of Administration

Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Intravenous

  • Subcutaneous

  • Parenteral

  • Topical

Molecule Type

Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins

  • Small molecule

  • Monoclonal antibody

  • Peptide

  • Polymer

  • Gene therapy

Learn How the Diabetic Retinopathy Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Diabetic Retinopathy Treatment Patterns

4. Diabetic Retinopathy – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Diabetic Retinopathy Late Stage Products (Phase-III)

7. Diabetic Retinopathy Mid-Stage Products (Phase-II)

8. Diabetic Retinopathy Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Diabetic Retinopathy Discontinued Products

13. Diabetic Retinopathy Product Profiles

14. Major Diabetic Retinopathy Companies in the Market

15. Key Products in the Diabetic Retinopathy Therapeutics Segment

16. Dormant and Discontinued Products

17. Diabetic Retinopathy Unmet Needs

18. Diabetic Retinopathy Future Perspectives

19. Diabetic Retinopathy Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:




About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight 

Stargardt Disease Market

“Stargardt Disease Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Stargardt Disease market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Stargardt Disease market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices

Related Articles